SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new data on its drug-Fc conjugate…Read More
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel DrugFc Conjugate CD388 at IDWeek 2023
